Biography

Dr. Peng Guo graduated from Jilin University with a B.S. in Chemistry and received his Ph.D. in Analytical Chemistry from University of Florida. He completed his Postdoctoral training at Harvard University and worked as an instructor at Havard Medical School before he joined the Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences in 2021.

Research Interests

A central theme in our lab is understanding how healthy and malignant vascular systems respond to drug delivery complexes (e.g., antibody-drug conjugates and exosomes), and how they can be therapeutically manipulated to treat diseases. We specifically work in three fields:

1. Understanding biological interactions between blood vessels and drug delivery systems
2. Discovering drug delivery targets via AI-based multi-omic screening
3. Developing bio-inspired drug delivery technologies and tools

Selected Publications

• Wei Q, Yang T, Zhu J, Zhang Z, Yang L, Zhang Y, Hu C, Chen J, Wang J, Tian X, Shimura T, Fang J, Ying J*, Fan M*, Guo P*, Cheng X*. Spatiotemporal quantification of HER2-targeting antibody-drug conjugate bystander activity and enhancement of solid tumor penetration. Clin Cancer Res. 2024;30(5):984-997.
• Guo P*, Huang J, Zhu B, Huang AC, Jiang L, Fang J, Moses MA*. A rationally designed ICAM1 antibody-drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Sci Adv. 2023;9(18):eabq7866.
• Zhang P*, Tao C, Lu Y, Li P, Wang X, Dai Y, Xi Y, Shimura T, Li X, Fang J, Yang L*, He D*, Guo P*. Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma. Adv Sci.2024;e2400203.
• Wei Q, Li P, Yang T, Zhu J, Sun L, Zhang Z, Wang L, Tian X, Chen J, Hu C, Xue J, Ma L, Shimura T, Fang J, Ying J, Guo P*, Cheng X*. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1.
• Zhu B, Wang X, Shimura T, Huang AC, Kong N, Dai Y, Fang J, Guo P*, Ying JE*. Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma. NPJ Precis Oncol. 2023;7(1):93.

Contacts

E-mail: guopeng@him.cas.cn

Office Room: 4-106

Hangzhou Institute of Medicine

Chinese Academy of Sciences

150 Dongfang Road, Qiantang District

Hangzhou, Zhejiang Province, China 310000